Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Uveitis: full-pipeline trial registry
6 of 21 indexed Uveitis trials are currently recruiting.
Corpus placement: #797 of 28,707 conditions by registered trial count.
21 US clinical trials · 6 currently recruiting · #797 of 28,707 conditions by registered trial count
Uveitis: 21 US clinical trials tracked, 6 recruiting.
Uveitis is the subject of 21 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is National Eye Institute (NEI), running 6 of these trials.
Enrollment posture brief
Registry condition uveitis
OPEN 6 | RECR 29% | LATE 6 | EARLY 4 | RANK #797 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Acne Scars (29% recruiting · 7 trials)
Uveitis lists 6 open slots (29% of 21 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Uveitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Uveitis is recruiting below its size-band peers.
6 of 21 indexed trials (28.6%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Uveitis research.
National Eye Institute (NEI) accounts for 6 of 21 trials (28.6%). 11 distinct sponsors appear on at least one study for this condition label.
-
Typical Uveitis enrolment sits around 131 participants.
Median target enrolment is 131 among the 20 trials that report a genuine target (sentinel values excluded). 7 of those (35%) plan for fewer than 100 participants.
-
Uveitis splits between interventional and observational designs.
11 interventional and 10 observational studies make up this index (52.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
21 total, page 1 of 1
Genetics of Uveitis
The Cleveland Clinic
NCT02357238
Analysis of Anterior Chamber Inflammation by Optical Coherence Tomography
The Cleveland Clinic
NCT01746537
RChildUV:Study on Non-infectious Chronic Uveitis in Pediatric Age
Meyer Children's Hospital IRCCS
NCT06273748
Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing
University of California, San Francisco
NCT05286203
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
Texas Retina Associates
NCT05486468
Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study
Quan Dong Nguyen
NCT06161415
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
Priovant Therapeutics
NCT06431373
Imaging Quantification of Inflammation (IQI)
The Cleveland Clinic
NCT04704609
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study
National Eye Institute (NEI)
NCT00116090
Genetics and Markers of Degenerative and Inflammatory Eye Diseases
National Eye Institute (NEI)
NCT00647439
Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial
JHSPH Center for Clinical Trials
NCT02623426
PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial
JHSPH Center for Clinical Trials
NCT02374060
Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis
Clearside Biomedical
NCT02595398
Intestinal Bacteria and Ocular Inflammatory Disease
National Eye Institute (NEI)
NCT01859299
Flare Photometry in Uveitis Patients
ChromoLogic
NCT01897935
Immune Indicators of Uveitis
National Eye Institute (NEI)
NCT00089739
MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301
Clearside Biomedical
NCT02952001
Optiquel® as Corticosteroid-sparing Therapy for Chronic Noninfectious Uveitis
National Eye Institute (NEI)
NCT01195948
Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis
Clearside Biomedical
NCT02255032
Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)
National Eye Institute (NEI)
NCT02911116
Study of Difluprednate in the Treatment of Uveitis
Sirion Therapeutics
NCT00501579
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
| Phase 3 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Uveitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Uveitis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Uveitis page
21 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Uveitis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Eye Institute (NEI) sponsors the most Uveitis trials on record, review their full trial history before evaluating a specific study. See National Eye Institute (NEI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Uveitis condition card totals 21 registered trials; most-linked intervention Intravitreal Ranibizumab 0.5 mg; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.